All In Biotech

Drug Trial Radar · NCT06046391

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Jul 6, 2023

Primary completion

Oct 19, 2023

Study completion Aug 6, 2024

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Allergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment, there is still a large number of patient (\~20%) are not well/adequately controlled. Anti-IgE antibody has been approved to treat moderate to severe AR by PMDA/Japan in 2020, demonstrating the efficacy of IgE blockade in the treatment of allergic rhinitis. The current study presents a novel anti-IgE antibody (LP-003) with higher affinity to IgE, stronger efficacy and longer half-life.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • LP-003 dose 1Biological

    Liquid in vial

  • LP-003 dose 2Biological

    Liquid in vial

  • PlaceboBiological

    Liquid in vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean nasal symptom scoreTime frame: peak pollen period(estimated average 4 weeks)

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

  • Dongfang Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Zhengzhou central hospital

    Zhengzhou, Henan, China

  • Changchun University of Chinese Medicine Affiliated Hospital

    Changchun, Jilin, China

  • Tonghua central hospital

    Tonghua, Jilin, China

  • Yan Bian Chao Yi Hospital

    Yanbian, Jilin, China

  • Yanbian University hospital

    Yanji, Jilin, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Yinchuan Peoples Hospital

    Yinchuan, Ningxia, China

  • Zibo central hospital

    Zibo, Shandong, China

  • Linfen Peoples Hospital

    Linfen, Shanxi, China

  • Second hospital of Shanxi Medical University University

    Taiyuan, Shanxi, China

  • The First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Xidian group hospital

    Xi’an, Shanxi, China

  • Tianjin Peoples Hospital

    Tianjing, Tianjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.